Table 2:
Treatment options | Side effects | Recovery time | Life after treatment | |
---|---|---|---|---|
Age at survey, in years | ||||
<50 | 26 (20.0%) | 36 (29.0%) | 23 (18.6%) | 40 (32.3%) |
50–64 | 128 (21.7%) | 168 (28.5%) | 148 (25.1%) | 203 (34.5%) |
65–74 | 111 (18.2%) | 144 (23.6%) | 114 (18.7%) | 153 (25.0%) |
≥75 | 94 (15.1%) | 113 (18.1%) | 97 (15.6%) | 124 (19.9%) |
Gender | ||||
Female | 171 (18.0%) | 227 (23.8%) | 189 (19.9%) | 261 (27.4%) |
Male | 188 (18.9%) | 234 (23.5%) | 193 (19.4%) | 259 (26.0%) |
Race/Ethnicity | ||||
White, non-Hispanic | 252 (15.7%) | 364 (22.7%) | 288 (17.9%) | 401 (24.9%) |
Other | 105 (32.2%) | 95 (29.1%) | 89 (27.3%) | 112 (34.3%) |
Education | ||||
Some high school | 52 (30.6%) | 58 (34.1%) | 41 (24.1%) | 51 (30.0%) |
High school graduate | 52 (15.1%) | 68 (19.7%) | 56 (16.2%) | 81 (23.5%) |
Some college | 123 (18.7%) | 151 (23.0%) | 136 (20.7%) | 190 (28.9%) |
College graduate | 61 (20.0%) | 84 (27.5%) | 62 (20.3%) | 78 (25.6%) |
Graduate school | 59 (15.4%) | 89 (23.2%) | 76 (19.8%) | 106 (27.6%) |
Cancer site | ||||
Colon | 242 (17.1%) | 295 (20.8%) | 258 (18.2%) | 338 (23.8%) |
Rectosigmoid | 19 (18.8%) | 22.8 (23%) | 15 (14.9%) | 23 (22.8%) |
Rectum | 98 (22.9%) | 143 (33.4%) | 109 (25.5%) | 159 (37.2%) |
Stage at diagnosis | ||||
0 | 37 (19.1%) | 40 (20.6%) | 30 (15.5%) | 40 (20.6%) |
1 | 96 (15.2%) | 117 (18.5%) | 121 (19.2%) | 147 (23.3%) |
2 | 85 (16.7%) | 114 (22.4%) | 99 (19.5%) | 140 (27.5%) |
3 | 112 (22.1%) | 152 (30.0%) | 104 (20.6%) | 160 (31.6%) |
4 | 24 (27.9%) | 29 (33.7%) | 24 (27.9%) | 26 (30.2%) |